This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
J Angst (1998). Sexual problems in healthy and depressed persons. International Clinical Psychopharmacology 13 (Suppl. 6), S1–S4.
BG Appelberg , EK Syvalahti , TE Koskinen , OP Mehtonen , TT Muhonen , HH Naukkarinen (2001). Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Journal of Clinical Psychiatry 62, 448–452.
S Aznar , Z Qian , R Shah , B Rahbek , GM Knudsen (2003). The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Research 959, 58–67.
RJ Bielski , L Cunningham , JP Horrigan , PD Londborg , WT Smith , K Weiss (2008). Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. Journal of Clinical Psychiatry 69, 571–577.
M Bonierbale , C Lancon , J Tignol (2003). The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Current Medical Research and Opinion 19, 114–124.
LD Cohn , BJ Becker (2003). How meta-analysis increases statistical power. Psychological Methods 8, 243–253.
R DerSimonian , N Laird (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177–188.
A Drago , C Crisafulli , A Sidoti , A Serretti (2011). The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Progress in Neurobiology 94, 418–460.
LF Fabre , CS Brown , LC Smith , LR Derogatis (2011 a). Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. Journal of Sexual Medicine 8, 1411–1419.
LF Fabre , AH Clayton , LC Smith , I Goldstein , LR Derogatis (2012). The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. Journal of Sexual Medicine 9, 821–829.
LF Fabre , LC Smith , LR DeRogatis (2011 b). Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain – a post hoc analysis. Journal of Sexual Medicine 8, 2569–2581.
MT Fava , SD Tarqum , AA Nierenberg , LS Bleicher , TA Carter , PC Wedel , R Hen , FH Gage , C Barlow (2012). An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. Journal of Psychiatric Research 46, 1553–1563.
AD Feiger , JF Heiser , RK Shrivastava , KJ Weiss , WT Smith , JM Sitsen , M Gibertini (2003). Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Journal of Clinical Psychiatry 64, 243–249.
M Hamilton (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23, 56–62.
JP Higgins , SG Thompson , JJ Deeks , DG Altman (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557–560.
I Hindmarch (2002). Beyond the monoamine hypothesis: mechanisms, molecules and methods. European Psychiatry 17 (Suppl. 3), 294–299.
SW Jenkins , DS Robinson , LF Fabre Jr., JJ Andary , ME Messina , LA Reich (1990). Gepirone in the treatment of major depression. Journal of Clinical Psychopharmacology 10, 77S–85S.
T Kishi , R Yoshimura , Y Fukuo , T Okochi , S Matsunaga , W Umene-Nakano , J Nakamura , A Serretti , CU Correll , JM Kane , N Iwata (2013). The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience 263, 105–118.
T Kato (2007). Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neurosciences 61, 3–19.
M Landen , G Bjorling , H Agren , T Fahlen (1998). A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Journal of Clinical Psychiatry 59, 664–668.
YD Lapierre , P Silverstone , RT Reesal , B Saxena , P Turner , D Bakish , J Plamondon , PM Vincent , RA Remick , C Kroft , R Payeur , D Rosales , R Lam , M Bologa (1998). A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. Journal of Clinical Psychopharmacology 18, 268–273.
B Le Francois , M Czesak , D Steubl , PR Albert (2008). Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55, 977–985.
S Leucht , C Corves , D Arbter , RR Engel , C Li , JM Davis (2009 a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41.
S Leucht , K Komossa , C Rummel-Kluge , C Corves , H Hunger , F Schmid , C Asenjo Lobos , S Schwarz , JM Davis (2009 b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152–163.
GK Matheson , DM Pfeifer , MB Weiberg , C Michel (1994). The effects of azapirones on serotonin1A neurons of the dorsal raphe. General Pharmacology 25, 675–683.
PJ McGrath , JW Stewart , FM Quitkin , S Wager , SW Jenkins , DG Archibald , JC Stringfellow , DS Robinson (1994). Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. Journal of Clinical Psychopharmacology 14, 347–352.
D Moher , A Liberati , J Tetzlaff , DG Altman ; PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal 339, b2535.
JL Moll , CS Brown (2011). The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. Journal of Sexual Medicine 8, 956–970.
SA Montgomery , M Asberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.
A Newman-Tancredi , MS Kleven (2011). Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berlin) 216, 451–473.
E Onder , U Tural (2003). Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. Journal of Affective Disorders 76, 223–227.
C Pinto , RP Souza , D Lioult , M Semeralul , JL Kennedy , JJ Warsh , AH Wong , VD Luca (2011). Parent of origin effect and allelic expression imbalance of the serotonin transporter in bipolar disorder and suicidal behaviour. European Archives of Psychiatry and Clinical Neuroscience 261, 533–538.
M Pompili , G Serafini , M Innamorati , AM Moller-Leimkuhler , G Giupponi , P Girardi , R Tatarelli , D Lester (2010). The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. European Archives of Psychiatry and Clinical Neuroscience 260, 583–600.
J Prins , B Olivier , SM Korte (2011). Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opinion on Investigational Drugs 20, 1107–1130.
K Rickels , A Derivan , N Kunz , A Pallay , E Schweizer (1996). Zalospirone in major depression: a placebo-controlled multicenter study. Journal of Clinical Psychopharmacology 16, 212–217.
DS Robinson , JM Sitsen , M Gibertini (2003). A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clinical Therapeutics 25, 1618–1633.
J Savitz , I Lucki , WC Drevets (2009). 5-HT(1A) receptor function in major depressive disorder. Progress in Neurobiology 88, 17–31.
E Schweizer , K Rickels , H Hassman , F Garcia-Espana (1998). Buspirone and imipramine for the treatment of major depression in the elderly. Journal of Clinical Psychiatry 59, 175–183.
SM Stahl , L Kaiser , J Roeschen , JM Keppel Hesselink , J Orazem (1998). Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. International Journal of Neuropsychopharmacology 1, 11–18.
H Tanaka , T Tatsuno , H Shimizu , A Hirose , Y Kumasaka , M Nakamura (1995). Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. General Pharmacology 26, 1765–1772.
PM Whitaker-Azmitia , M Druse , P Walker , JM Lauder (1996). Serotonin as a developmental signal. Behavioural Brain Research 73, 19–29.
K Yamada , G Yagi , S Kanba (2003). Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial. Psychiatry and Clinical Neurosciences 57, 183–187.
K Zuideveld , J Rusic-Pavletic , H Maas , L Peletier , P Van der Graaf , M Danhof (2002). Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. Journal of Pharmacology and Experimental Therapeutics 303, 1130–1137.